Aprea Therapeutics (APRE) Interest & Investment Income (2018 - 2026)

Aprea Therapeutics (APRE) has reported Interest & Investment Income for 9 consecutive years, with $358923.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Interest & Investment Income rose 101.61% year-over-year to $358923.0 in Q2 2026; TTM through Jun 2026 was $763040.0, a 24.16% decrease from a year earlier, with the FY2025 full-year figure at $652086.0, down 49.42% from the prior year.
• Interest & Investment Income was $358923.0 for Q2 2026 at Aprea Therapeutics, up from $134784.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $382374.0 in Q2 2024 and troughed at $1971.0 in Q1 2022.
• A 5-year average of $228207.6 and a median of $249746.0 in 2022 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income soared 458048.48% in 2022 and sank 56.8% in 2025, its largest moves.
• Over 5 years, Interest & Investment Income stood at $243082.0 in 2022, then increased by 27.65% to $310287.0 in 2023, then slipped by 11.49% to $274626.0 in 2024, then sank by 56.79% to $118664.0 in 2025, then jumped by 202.47% to $358923.0 in 2026.
• The last three Interest & Investment Income figures came in at $358923.0 (Q2 2026), $134784.0 (Q1 2026), and $118664.0 (Q4 2025), per Business Quant data.